Issue navigation
Volume 115, Issue 1, January 2023
Editorials
Weighing evidence: robustness vs quantity
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 1–3, https://doi.org/10.1093/jnci/djac186
Early-life exposures and adulthood cancer risk: A life course perspective
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 4–7, https://doi.org/10.1093/jnci/djac193
A methylation-based prognostic signature in stage II colorectal patients: Considerations for clinical adoption
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 8–11, https://doi.org/10.1093/jnci/djac184
Diverticular disease and cancer risk: More than a gut feeling
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 12–13, https://doi.org/10.1093/jnci/djac191
Commentaries
Augmenting randomized clinical trial data with historical control data: Precision medicine applications
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 14–20, https://doi.org/10.1093/jnci/djac185
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 21–28, https://doi.org/10.1093/jnci/djac166
Review
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 29–42, https://doi.org/10.1093/jnci/djac205
Articles
Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 43–51, https://doi.org/10.1093/jnci/djac192
DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 52–61, https://doi.org/10.1093/jnci/djac183
Cancer risk in patients with diverticular disease: A nationwide cohort study
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 62–70, https://doi.org/10.1093/jnci/djac190
Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 71–82, https://doi.org/10.1093/jnci/djac178
Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 83–92, https://doi.org/10.1093/jnci/djac180
Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 93–103, https://doi.org/10.1093/jnci/djac188
Long-term pelvic fracture and overall mortality risk after pelvic cancer and pelvic radiation
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 104–111, https://doi.org/10.1093/jnci/djac197
Correspondence
RE: Informing women about overdetection in breast cancer screening: Two-year outcomes from a randomized trial
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Pages 112–113, https://doi.org/10.1093/jnci/djac200
Response
Response to Kraut
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Page 114, https://doi.org/10.1093/jnci/djac201
Correction
Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade
JNCI: Journal of the National Cancer Institute, Volume 115, Issue 1, January 2023, Page 115, https://doi.org/10.1093/jnci/djac207
